King Pharmaceuticals Reports Publication Of Binodenoson Phase II Clinical Data In AHA Journal Circulation
Aderis’ partner King Pharmaceuticals today reports that the results of Phase II trials of binodenoson, an adenosine A2A receptor agonist for cardiac pharmacologic stress-imaging, are available in the American Heart Association’s journal Circulation
Hopkinton, MA - Jan 29, 2004 - Aderis Pharmaceutical's partner for binodenoson, King Pharmaceuticals, reports that the results from Phase II trials of binodenoson are to be published in the February 3, 2004 issue of Circulation. The paper was accepted as a rapid track publication and can be viewed pre- publication at http://circ.ahajournals.org/.
"At Aderis, we are excited about the progress of our product candidates and their potential ability to improve quality of life for millions of people. We are committed to helping patients and investors understand our progress as we achieve corporate and clinical milestones."
-Kenneth L. Rice, Jr.,
Chief Commercial Officer, Aderis Pharmaceuticals
back to top
